

Certificate of Analysis for NR-54977

Vector pαH Containing the Human Coronavirus, 229E Recombinant Spike Ectodomain Gene

Catalog No. NR-54977

This reagent is the tangible property of the U.S. Government.

Product Description:

NR-54977 is an expression vector containing the human coronavirus, 229E recombinant spike ectodomain gene insert (codon optimized) encoding S1 ectodomain residues 1-1108 (GenPept: <u>AOG74783.1</u>) linked to C-terminal T4 fibritin trimerization domain (foldon), an HRV3C cleavage site, octa His-tag and 2X Strep-tag® II. Recombinant S ectodomain trimer is stabilized in the prefusion conformation by two proline substitutions (I869P and I870P)^{1,2} NR-54977 contains the beta-lactamase gene, *bla*, to provide transformant selection through ampicillin resistance in *Escherichia coli* (*E. coli*). The deposited plasmid was transformed into One Shot™ TOP10 *Escherichia coli* (Invitrogen™ C404003), grown in Terrific broth with ampicillin (100 µg per mL) for 1 day at 37°C in an aerobic atmosphere, extracted using a Plasmid *Plus* Maxi Kit (QIAGEN® 12963) and vialed in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

Lot: 70043624 Manufacturing Date: 18MAY2021

TEST	SPECIFICATIONS	RESULTS
Next-Generation DNA Sequencing (pre-vial)	~ 7530 base pairs	7522 base pairs ¹
Genotypic Analysis Sequencing of S glycoprotein insert (~ 3560 base pairs)	≥ 99% sequence identity to depositor's sequence C-terminal T4 foldon trimerization domain confirmed C-terminal HRV3C protease cleavage site confirmed C-terminal octa-histidine tag confirmed C-terminal 2X Strep-tag® II confirmed	100% sequence identity to depositor's sequence ² C-terminal T4 foldon trimerization domain confirmed C-terminal HRV3C protease cleavage site confirmed C-terminal octa-histidine tag confirmed C-terminal 2XStrep-tag® II confirmed
Antibiotic Resistance Ampicillin (encoded by beta-lactamase gene bla)	bla sequence present	bla sequence present
Concentration by PicoGreen® Measurement	≥ 2 µg/mL	0.4 μg in 20 μL/vial (20 μg/mL)
Amount per Vial	Report results	0.4 μg/vial
OD ₂₆₀ /OD ₂₈₀ Ratio	1.7 to 2.1	2.0
Effective Bacterial Transformation Invitrogen™ One Shot™ TOP10 <i>E. coli</i>	≥ 50 colonies/ng	51 colonies/ng

¹The sequence was assembled pre-vial using the depositor's predicted sequence as the reference sequence. The complete plasmid sequence and map are provided on the BEI Resources webpage.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898

²The NR-54977 insert was codon optimized for mammalian expression but has 100% amino acid identity with human coronavirus, 229E S glycoprotein (GenPept: AOG74783.1) other than the stabilization mutations.



Certificate of Analysis for NR-54977

/Sonia Bjorum Brower/
Sonia Bjorum Brower

01 JUN 2023

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® and the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898